These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35015785)

  • 41. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
    Elishmereni M; Kheifetz Y; Shukrun I; Bevan GH; Nandy D; McKenzie KM; Kohli M; Agur Z
    Prostate; 2016 Jan; 76(1):48-57. PubMed ID: 26419619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
    Aragon-Ching JB; Williams KM; Gulley JL
    Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.
    Fallara G; Belladelli F; Robesti D; Raggi D; Nocera L; Marandino L; Galsky MD; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
    Crit Rev Oncol Hematol; 2022 Nov; 179():103801. PubMed ID: 36031173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
    Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
    Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
    Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
    Dudzinski SO; Cameron BD; Wang J; Rathmell JC; Giorgio TD; Kirschner AN
    J Immunother Cancer; 2019 Aug; 7(1):218. PubMed ID: 31412954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A QSP model of prostate cancer immunotherapy to identify effective combination therapies.
    Coletti R; Leonardelli L; Parolo S; Marchetti L
    Sci Rep; 2020 Jun; 10(1):9063. PubMed ID: 32493951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis.
    Liang Y; Rong E; Qian J; Ma C; Hu J
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):327-335. PubMed ID: 35079116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
    World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of chemotherapy in metastatic prostate cancer.
    Riaz IB; Sweeney CJ
    Curr Opin Urol; 2022 May; 32(3):292-301. PubMed ID: 35552310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the tumor-immune microenvironment in prostate cancer.
    Dong L; Myers KV; Pienta KJ
    Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
    Sonpavde G; Huang A; Wang L; Baser O; Miao R
    BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells.
    Negri A; Marozzi M; Trisciuoglio D; Rotili D; Mai A; Rizzi F
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2163242. PubMed ID: 36629431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.